

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant <b>Masayuki Tsuchiya <i>et al.</i></b>	
		Filing Date <b>August 25, 2006</b>	
		Group Art Unit <b>1643</b>	
(37 CFR §1.98(b))			

U.S. Patent Documents						
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass
	1	2008/0248037	10/09/2008	Li <i>et al.</i>		
	2	4,946,778	08/07/1990	Ladner <i>et al.</i>		
	3	7,115,373	10/03/2006	Hashida <i>et al.</i>		

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	4	WO 99/12973	03/18/1999	WIPO			English abstract	
	5	WO 2004/003019	01/08/2004	WIPO				
	6	WO 2004/087763	10/14/2004	WIPO			English abstract	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	7	ARNDT <i>et al.</i> , "Factors Influencing the Dimer to Monomer Transition of an Antibody Single-Chain Fv Fragment," <i>Biochemistry</i> , 37:12918-12926 (1998)
	8	DUFNER <i>et al.</i> , "Harnessing phage and ribosome display for antibody optimization," <i>Trends Biotechnol.</i> , 24(11):523-529 (2006)
	9	ICHIKAWA <i>et al.</i> , "Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity," <i>Nat. Med.</i> , 7:954-960 (2001)
	10	KUMAR <i>et al.</i> , "Molecular cloning and expression of the fabs of human autoantibodies in <i>Escherichia coli</i> ," <i>The Journal of Biological Chemistry</i> , 275(41):35129-35136 (2000)
	11	MATEO <i>et al.</i> , "CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia," <i>Nat. Med.</i> , 5(11):1277-1284 (1999)
	12	PAUL, <i>Fundamental Immunology</i> , 3rd Edition, Raven Press, NY, Chapter 8, pp. 292-295 (1993)
	13	SACKSTEIN, "The lymphocyte homing receptors: gatekeepers of the multistep paradigm," <i>Current Opinion in Hematology</i> , 12:444-450 (2005)
	14	SMITH-GILL <i>et al.</i> , "Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens," <i>The Journal of Immunology</i> , 139:4135-4144 (1987)
	15	SONG <i>et al.</i> , "Light chain of natural antibody plays a dominant role in protein antigen binding," <i>Biochemical and Biophysical Research Communications</i> , 268:390-394 (2000)
	16	WAKALEE <i>et al.</i> , <i>Ann. Oncol.</i> On-line publication (7/24/2009)
	17	WARD <i>et al.</i> , "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , 341:544-546 (1989)
	18	WHITLOW <i>et al.</i> , "Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv," <i>Protein Eng.</i> , 7(8):1017-1026 (1994)

Examiner Signature  /Anne M. Gussow/	Date Considered  12/02/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Masayuki Tsuchiya <i>et al.</i>	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	19	YAGITA <i>et al.</i> , "TRAIL and its receptors as targets for cancer therapy," <i>Cancer Sci.</i> , 95:777-783 (2004)
	20	FISH & RICHARDSON P.C., Amendment in Reply to Action dated April 15, 2009 in U.S. App. Ser. No. 10/551,504, filed August 14, 2009, 19 pages
	21	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed September 15, 2009, 22 pages
	22	KLARQUIST SPARKMAN, LLP Response to Restriction Requirement dated May 26, 2009 in U.S. App. Ser. No. 10/582,654, filed June 23, 2009, 2 pages
	23	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Office Action in U.S. App. Ser. No. 10/582,654, mailed September 1, 2009, 36 pages
	24	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed September 11, 2009, 24 pages
	25	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/257,864, mailed February 1, 2006, 14 pages
	26	U.S. EXAMINER PENSEE T. DO, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,176, mailed October 19, 2009, 6 pages
	27	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed October 27, 2009, 4 pages

Examiner Signature /Anne M. Gussow/	Date Considered 12/02/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	